IMMUNOVANT
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
IMMUNOVANT
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.immunovant.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Microsoft Exchange Online Amazon
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Stock Details
Investors List
Roivant Sciences
Roivant Sciences investment in Post-IPO Equity - Immunovant
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Immunovant
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-25 | Immunovant Appoints Mark Levine as Chief Legal Officer |
| 2021-09-15 | Immunovant Appoints Renee Barnett as Chief Financial Officer |
Official Site Inspections
http://www.immunovant.com Semrush global rank: 852.69 K Semrush visits lastest month: 44.46 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immunovant"
Our Leadership :: Immunovant, Inc. (IMVT)
Prior to joining Immunovant, she was the Vice President, Quality & Regulatory Clinical Trials Division, Thermo Fisher Scientific, responsible for leading the global quality & regulatory organization to support their clinical trial division in …See details»
Values & Culture :: Immunovant, Inc. (IMVT)
At Immunovant, you will be engaged intellectually through challenging work, you will apply your passion to the needs of patients, and you will add high energy to our ongoing momentum. ... There is opportunity for each person to make a …See details»
About Us :: Immunovant, Inc. (IMVT)
Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of …See details»
Immunovant - LinkedIn
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing ...See details»
Immunovant - Crunchbase Company Profile & Funding
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product …See details»
Immunovant, Inc. (IMVT) Company Profile & Facts
See the company profile for Immunovant, Inc. (IMVT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
Immunovant, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Mar 6, 2025 Immunovant also plans to announce additional data from the batoclimab proof-of-concept study in GD including 6-month, treatment-free remission data designed to further …See details»
Immunovant Company Profile - Craft
Oct 29, 2024 Immunovant is a biopharmaceutical company focused on autoimmune diseases. Its product IMVT-1401 is a human monoclonal antibody targeting the neonatal Fc receptor …See details»
Immunovant Announces Leadership Changes with Eric Venker
1 day ago Immunovant, Inc. announced significant leadership changes and strategic developments, including the appointment of Eric Venker, M.D. as CEO and Tiago Girao as …See details»
Immunovant replaces CEO, makes other changes as …
1 day ago Immunovant was spun out of Roivant in 2019 to develop a pipeline of drugs to treat autoimmune disorders. While Immunovant is its own publicly traded entity, Roivant retains 57% ownership, giving ...See details»
Mission, Vision & Core Values of Immunovant
Dec 17, 2024 Immunovant is a pioneering biopharmaceutical company dedicated to revolutionizing the treatment of autoimmune diseases through innovative therapies. Our …See details»
[JPM2025] HanAll Biopharma’s US partner says its drug is …
Jan 15, 2025 Immunovant is a U.S. partner of Korean drug development company HanAll Biopharma and is in clinical development of batoclimab (IMVT-1401 or HL161 in HanAll’s …See details»
Immunovant narrows R&D focus as Roivant execs join C-suite
1 day ago Immunovant will face entrenched rivals if it wins approval in diseases such as myasthenia gravis, where argenx received FDA authorization in 2021, but the R&D plan also …See details»
Immunovant - Funding, Financials, Valuation & Investors
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. New. Resources. Advanced Search. ... How much funding …See details»
Immunovant Shares Dive After Roivant Pushes C-Suite Changes, …
1 day ago Roivant Sciences is making serious changes to subsidiary Immunovant (), announcing Monday a series of C-suite changes and new disease targets for Immunovant's leading drug.. …See details»
For Investors :: Immunovant, Inc. (IMVT)
Mar 18, 2025 Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 . Investor Relations. Immunovant, Inc. Investor Relations [email protected]. Transfer Agent. …See details»
Company Information :: Immunovant, Inc. (IMVT)
Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 . INVESTOR RELATIONS. Immunovant, Inc. Investor Relations [email protected]. TRANSFER AGENT. Continental …See details»
What is Immunovant? Company Culture, Mission, Values
How do job seekers rate their interview experience at Immunovant? 18% of job seekers rate their interview experience at Immunovant as positive. Candidates give an average difficulty score of …See details»
Immunovant Announces Leadership Changes with Eric Venker
1 day ago Immunovant announced a leadership change with Eric Venker, M.D., currently President and COO of Roivant, appointed as CEO, succeeding Dr. Pete Salzmann, who has …See details»
Immunovant makes leadership changes - MSN
Immunovant (NASDAQ:IMVT) has named Eric Venker, Roivant’s current president, as its new chief executive officer, replacing Pete Salzmann who retired from his position as CEO and …See details»